CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,197 enrolled
Drug / intervention
Edoxabanprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02950168
NCT02950168N/ACompleted
CompareCT.gov

Edoxaban Management in Diagnostic and Therapeutic Procedures

Daiichi Sankyo·observational·Posted Oct 31, 2016·Updated Feb 5, 2020

In Brief

An observational study evaluating Edoxaban for Atrial Fibrillation and Venous Thromboembolism. Completed, enrolled 1,197 participants.

Detailed Summary

Patients receiving Novel Oral Anticoagulation (NOACs) undergo diagnostic and therapeutic procedures at a rate of 10% per year. Short half-lives and rapid onset of action allow for short periods of NOAC interruption without heparin bridging. There is only minimal information on the peri-procedural usage pattern of edoxaban and the related outcome data currently available. Therefore, further real-world clinical data on the peri-procedural usage pattern of edoxaban within any diagnostic or interventional procedure in patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE) will be collected in this registry.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Venous Thromboembolism
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 31, 2016
Enrollment StartNov 1, 2016
Primary CompletionJul 26, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.7 years ago

Interventions

Edoxabanprocedure

Edoxaban according to Summary of Product Characteristic (SMPC)